<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613234</url>
  </required_header>
  <id_info>
    <org_study_id>128EEG</org_study_id>
    <nct_id>NCT02613234</nct_id>
  </id_info>
  <brief_title>Efficacy of 128-channel EEG Combined With BESA Dipole Localization and Intervention on Brain Waves for Epilepsy</brief_title>
  <official_title>Efficacy of 128-channel Electroencephalograph Combined With BESA Dipole Localization Method and Intervention on Brain Waves for Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of epilepsy is about 0.5% to 1% worldwide, with high disability and mortality&#xD;
      rate. The 128-channel electroencephalograph (EEG), combined with BESA dipole localization&#xD;
      method, is able to provide more specific information about the brain activity and find out&#xD;
      the epileptogenic focus. Based on this novel EEG recording method, cathode transcranial&#xD;
      direct current stimulation (tDCS) targeting the epileptogenic focus can be used to decrease&#xD;
      the excitability of the cortex, thus reducing the frequency of seizures. A single-center&#xD;
      double-blinded randomized controlled and open-label extension trial will be carried out to&#xD;
      study the efficacy of 128-channel electroencephalograph combined with BESA dipole&#xD;
      localization method and Intervention on brain waves for epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The prevalence of epilepsy is about 0.5% to 1% worldwide, with high disability&#xD;
      and mortality rate. The 128-channel electroencephalograph (EEG), combined with Brain&#xD;
      Electrical Source Analysis (BESA) dipole localization method, is able to provide more&#xD;
      specific information about the brain activity and find out the epileptogenic focus. Based on&#xD;
      this novel EEG recording method, cathode transcranial direct current stimulation (tDCS)&#xD;
      targeting the epileptogenic focus can be used to decrease the excitability of the cortex,&#xD;
      thus reducing the frequency of seizures.&#xD;
&#xD;
      Methods: A single-center double-blinded randomized controlled and open-label extension trial&#xD;
      will be carried out to study the efficacy of 128-channel electroencephalograph combined with&#xD;
      BESA dipole localization method and Intervention on brain waves for epilepsy. Adult patients&#xD;
      aged 18 to 65 years old with epilepsy will be recruited. The study contains two stages. At&#xD;
      the first randomized controlled stage, patients will be randomly assigned to experimental and&#xD;
      control group with a 1:1 sqrt allocation and undergo five daily sessions of brain-wave&#xD;
      intervention by cathode tDCS （20min, 1mA） targeting the epileptogenic focus, which is&#xD;
      confirmed by 128-channel EEG and BESA dipole localization method. Active intervention will be&#xD;
      carried out for the experimental group, and sham intervention ( the stimulator will be turned&#xD;
      off after 5s) for the control group. The frequency of seizures, the number of epileptiform&#xD;
      discharges, the diffusion tensor imaging (DTI) of magnetic resonance imaging (MRI), the&#xD;
      cognitive function, the psychology and the life quality will be measured before (baseline), 1&#xD;
      hour, 4 weeks and 12 weeks after the last intervention to evaluate the changes after&#xD;
      intervention. At the second open-label extension stage, all the patients will undergo five&#xD;
      daily sessions of active intervention (20min, 1mA) and be followed up for 12 weeks similar to&#xD;
      the first stage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Actual">May 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure frequency</measure>
    <time_frame>6 months</time_frame>
    <description>The frequency of seizures using diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MMSE</measure>
    <time_frame>6 months</time_frame>
    <description>The cognitive function using Mini-mental state examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MoCA</measure>
    <time_frame>6 months</time_frame>
    <description>The cognitive function using Montreal cognitive assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AVLT</measure>
    <time_frame>6 months</time_frame>
    <description>The cognitive function using auditory verbal learning test (</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDMT</measure>
    <time_frame>6 months</time_frame>
    <description>The cognitive function using symbol digit modalities test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CWT</measure>
    <time_frame>6 months</time_frame>
    <description>The cognitive function using Stroop color word test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPQ</measure>
    <time_frame>6 months</time_frame>
    <description>The psychology evaluation using Eysenck personality questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAMD-17</measure>
    <time_frame>6 months</time_frame>
    <description>The psychology evaluation using Hamilton rating scale for depression-17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCL-90</measure>
    <time_frame>6 months</time_frame>
    <description>The psychology evaluation using symptom check list-90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOLIE-31</measure>
    <time_frame>6 months</time_frame>
    <description>The life quality using quality of life in epilepsy-31</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epileptiform discharges</measure>
    <time_frame>6 months</time_frame>
    <description>The number of epileptiform discharges using 30min EEG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI analysis</measure>
    <time_frame>6 months</time_frame>
    <description>Graph theory-based fMRI analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Intervention on brain waves by cathode tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Intervention on brain waves by cathode tDCS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cathode tDCS</intervention_name>
    <description>At the first randomized controlled stage, the experimental group will undergo five daily sessions of active brain-wave intervention by cathode tDCS (20min, 1mA) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.&#xD;
At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA).</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham cathode tDCS</intervention_name>
    <description>At the first randomized controlled stage, the control group will undergo five daily sessions of sham brain-wave intervention by cathode tDCS (20min, 1mA, the stimulator will be turned off after 5s) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.&#xD;
At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA).</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with epilepsy at least 1 year according to the 2010 International League&#xD;
             Against Epilepsy (ILAE) criteria.&#xD;
&#xD;
          -  Aged 18 to 65 years old.&#xD;
&#xD;
          -  The seizure is not well-controlled by antiepileptic drugs, the patient cannot tolerant&#xD;
             the side effect of antiepileptic drugs, or the patient is not satisfied with the&#xD;
             curative effect.&#xD;
&#xD;
          -  The dose of antiepileptic drugs must be stable in the last 4 weeks.&#xD;
&#xD;
          -  The patient or his/her family member is able to recording the frequency of seizures&#xD;
             and complete the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of status epilepticus in the last 12 weeks according to the definition by&#xD;
             Neurocritical Care Society (NCS) 2012.&#xD;
&#xD;
          -  History of transcranial direct current stimulation, repetitive transcranial magnetic&#xD;
             stimulation, vagus nerve stimulation, trigeminal nerve stimulation or deep brain&#xD;
             stimulation. History of pacemaker or other metal equipment implantation.&#xD;
&#xD;
          -  History of skull defect, brain tumor, encephalitis, progressive encephalopathy and&#xD;
             other progressive diseases of central nervous system.&#xD;
&#xD;
          -  History of severe cardiac, hepatic, renal, hematologic diseases, or other progressive&#xD;
             and systemic diseases, or during pregnancy.&#xD;
&#xD;
          -  History of major depression and other mental disturbance, color blindness, hearing or&#xD;
             language disorder who is not able to complete the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, China</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 15, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Weifeng Peng</investigator_full_name>
    <investigator_title>Vice Professor, Neurology Department, Investigator, Clinical Doctor</investigator_title>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>128-Channel EEG</keyword>
  <keyword>Dipole Localization</keyword>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

